Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Not Confirmed
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Not Confirmed
Not Confirmed
18-19 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
American Pharma SummitAmerican Pharma Summit
Industry Trade Show
Not Confirmed
18-19 November, 2024
Pharma Manufacturing 2...Pharma Manufacturing 2024
Industry Trade Show
Not Confirmed
18-19 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
12 Nov 2024
// BUSINESSWIRE
25 Sep 2024
// BUSINESSWIRE
19 Sep 2024
// BUSINESSWIRE
12 Aug 2024
// BUSINESSWIRE
30 Jul 2024
// BUSINESSWIRE
10 Jul 2024
// BUSINESSWIRE
Details:
BRC-001 is a first-in-class cannabinoid therapeutic, which is being investigating in a clinical trial as a supportive care in breast cancer.
Lead Product(s): Cannabidiol
Therapeutic Area: Oncology Brand Name: BRC-001
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
City of Hope, BRC Start Clinical Trial for Cannabinoid in Breast Cancer
Details : BRC-001 is a first-in-class cannabinoid therapeutic, which is being investigating in a clinical trial as a supportive care in breast cancer.
Brand Name : BRC-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 12, 2024
Details:
Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Lead Product(s): CMV-MVA Triplex
Therapeutic Area: Infections and Infectious Diseases Brand Name: CMV-MVA Triplex
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Helocyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 16, 2023
Lead Product(s) : CMV-MVA Triplex
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Helocyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Brand Name : CMV-MVA Triplex
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 16, 2023
Details:
CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.
Lead Product(s): NSC.CRAd-S-pk7
Therapeutic Area: Oncology Brand Name: CLD-101
Study Phase: Phase IProduct Type: Cell and Gene therapy
Recipient: Calidi Biotherapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2023
Lead Product(s) : NSC.CRAd-S-pk7
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Calidi Biotherapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.
Brand Name : CLD-101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 18, 2023
Details:
Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Lead Product(s): Bisantrene
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Race Oncology Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 10, 2023
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Race Oncology Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Race Executes Global License Agreement with City of Hope to Access FTO IP
Details : Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 10, 2023
Details:
CYTO-102 to be an off-the-shelf cell therapy that can directly kill cancer cells, broadly stimulate the body’s own endogenous immune system, and enhance tumor killing through generation of a highly effective immune response ultimately leading to improved patient outcomes.
Lead Product(s): CYTO-102,Atezolizumab
Therapeutic Area: Oncology Brand Name: CYTO-102
Study Phase: Phase IProduct Type: Cell and Gene therapy
Recipient: CytoImmune Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Lead Product(s) : CYTO-102,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : CytoImmune Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CYTO-102 to be an off-the-shelf cell therapy that can directly kill cancer cells, broadly stimulate the body’s own endogenous immune system, and enhance tumor killing through generation of a highly effective immune response ultimately leading to improv...
Brand Name : CYTO-102
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 28, 2022
Details:
City of Hope exclusively licensed patent rights covering Vaxina (CF33) to Imugene Limited, a company developing novel therapies that activate the immune system against cancer. Imugene has given CF33-hNIS the name Vaxinia.
Lead Product(s): CF33-hNIS,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Vaxina
Study Phase: Phase IProduct Type: Vaccine
Recipient: Imugene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Lead Product(s) : CF33-hNIS,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Imugene
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : City of Hope exclusively licensed patent rights covering Vaxina (CF33) to Imugene Limited, a company developing novel therapies that activate the immune system against cancer. Imugene has given CF33-hNIS the name Vaxinia.
Brand Name : Vaxina
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 18, 2022
Details:
A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical trial.
Lead Product(s): COH04S1
Therapeutic Area: Infections and Infectious Diseases Brand Name: COH04S1
Study Phase: Phase IIProduct Type: Vaccine
Recipient: GeoVax Labs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Lead Product(s) : COH04S1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : GeoVax Labs
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical tria...
Brand Name : COH04S1
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 10, 2022
Details:
MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency and T cell persistence.
Lead Product(s): MB-101
Therapeutic Area: Oncology Brand Name: MB-101
Study Phase: Phase IProduct Type: Large molecule
Recipient: Mustang Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Lead Product(s) : MB-101
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Mustang Bio
Deal Size : Not Applicable
Deal Type : Not Applicable
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’...
Details : MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency ...
Brand Name : MB-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 09, 2022
Details:
OST compounds are natural products derived from plants native of tropical and subtropical America, which have been used in alternative and traditional medicine. At City of Hope, these compounds will undergo pharmacologic and toxicologic testing at specialized laboratories.
Lead Product(s): Plant-derived OST Compounds
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Undisclosed
Recipient: Ostentus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 27, 2022
Lead Product(s) : Plant-derived OST Compounds
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Ostentus Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : OST compounds are natural products derived from plants native of tropical and subtropical America, which have been used in alternative and traditional medicine. At City of Hope, these compounds will undergo pharmacologic and toxicologic testing at specia...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 27, 2022
Details:
The Lancet Oncology study is a proof of principle that targeting KRAS G12C with a small molecule KRAS G12C inhibitor, sotorasib, can lead to tumor shrinkage and meaningful duration of disease control in a patient population that otherwise has very limited treatment options.
Lead Product(s): Sotorasib
Therapeutic Area: Oncology Brand Name: Lumakras
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2021
Details : The Lancet Oncology study is a proof of principle that targeting KRAS G12C with a small molecule KRAS G12C inhibitor, sotorasib, can lead to tumor shrinkage and meaningful duration of disease control in a patient population that otherwise has very limite...
Brand Name : Lumakras
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 14, 2021
ABOUT THIS PAGE
City of Hope is a supplier offers 1 products (APIs, Excipients or Intermediates).
Find a price of Fluoride Ion F-18 bulk with DMF offered by City of Hope
LOOKING FOR A SUPPLIER?